Indoco Remedies Ltd

Indoco Remedies Other Announcement

Indoco Remedies disclosed an unsolicited Crisil ESG rating of 'Crisil ESG 60'. The company notes it did not engage Crisil for the assessment.

Indoco Remedies Merger & Restructuring Worth ₹0.01 Cr

Indoco Remedies will incorporate a new wholly owned subsidiary, Warren Lifesciences Private Limited, for the pharmaceutical business with an initial capital of Rs. 1 Lakh.

Value

₹0.01 Cr

Indoco Remedies Annual General Meeting

Indoco Remedies filed proceedings of its 79th AGM held on 17 September 2026. Shareholders voted on nine resolutions including dividend and borrowing limits.

Indoco Remedies Promoter Buying

Indoco Remedies promoter Aditi M. Panandikar and PAC bought 38,930 shares on the open market, raising aggregate holding to 7.30%. No transaction price is disclosed in the filing.

Promoter stake change

+0.04%

Indoco Remedies Promoter Buying: ₹0.92 Cr

Promoters Aditi M. Panandikar, Madhura Suresh Kare, Suresh G. Kare, and Aruna Suresh Kare acquired Indoco Remedies Ltd shares via market purchases, totaling ₹0.92 Crore.

Value

₹0.92 Cr

Indoco Remedies Business Update

Indoco Remedies received seven USFDA observations in Form 483 for its Plant II (Sterile) facility in Goa following an inspection from August 27 to September 4, 2026.

Indoco Remedies Promoter Buying: ₹0.1 Cr

Promoters Aditi M. Panandikar and Madhura Suresh Kare each purchased 2,000 shares of Indoco Remedies from the open market. This reflects an increased promoter stake.

Value

₹0.10 Cr